MedPath

UNIVERSITY OF WASHINGTON

UNIVERSITY OF WASHINGTON logo
🇺🇸United States
Ownership
Private
Established
1861-01-01
Employees
10K
Market Cap
-
Website
https://www.cs.washington.edu

Clinical Trials

1.4k

Active:73
Completed:858

Trial Phases

6 Phases

Early Phase 1:9
Phase 1:127
Phase 2:208
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1197 trials with phase data)• Click on a phase to view related trials

Not Applicable
704 (58.8%)
Phase 2
208 (17.4%)
Phase 1
127 (10.6%)
Phase 4
91 (7.6%)
Phase 3
58 (4.8%)
Early Phase 1
9 (0.8%)

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

Recruiting
Conditions
Bladder Cancer
Recurrent Bladder Cancer
Non-muscle Invasive Bladder Cancer (NMIBC)
First Posted Date
2025-11-05
Last Posted Date
2025-11-05
Lead Sponsor
University of Washington
Target Recruit Count
408
Registration Number
NCT07225127
Locations
🇺🇸

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

🇺🇸

University of Iowa, Iowa City, Iowa, United States

🇺🇸

University of North Carolina, Chapel Hill, North Carolina, United States

and more 3 locations

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Not Applicable
Not yet recruiting
Conditions
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1
Lymphoblastic Lymphoma
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
First Posted Date
2025-11-04
Last Posted Date
2025-11-04
Lead Sponsor
University of Washington
Target Recruit Count
33
Registration Number
NCT07224100
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Superiority Trial of Radiofrequency Ablation for Low Back Pain

Not Applicable
Not yet recruiting
Conditions
Chronic Low Back Pain (CLBP)
First Posted Date
2025-10-29
Last Posted Date
2025-10-29
Lead Sponsor
University of Washington
Target Recruit Count
300
Registration Number
NCT07222462
Locations
🇺🇸

Emory Musculoskeletal Institute, Atlanta, Georgia, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

University of Utah Orthopaedic Center/PM&R, Salt Lake City, Utah, United States

The Lateral, Anterior, Medial (LAM) Femoral Cutaneous Block: A Case Series Harborview Medical Center, Seattle, WA

Recruiting
Conditions
Regional Anesthesia
Burn
Skin Grafting
First Posted Date
2025-10-28
Last Posted Date
2025-11-04
Lead Sponsor
University of Washington
Target Recruit Count
10
Registration Number
NCT07221903
Locations
🇺🇸

Harborview Medical Center, Seattle, Washington, United States

Magic Bowl Virtual Reality Analgesia

Not Applicable
Completed
Conditions
Pain Acute
First Posted Date
2025-09-25
Last Posted Date
2025-09-25
Lead Sponsor
University of Washington
Target Recruit Count
24
Registration Number
NCT07192822
Locations
🇺🇸

University of Washington, Seattle, Washington, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 274
  • Next

News

QIAGEN Acquires Parse Biosciences for $225 Million to Expand Single-Cell Analysis Capabilities

QIAGEN announced the acquisition of Parse Biosciences for $225 million upfront plus potential milestone payments, expanding its portfolio into the rapidly growing single-cell sequencing market.

Parse Biosciences Wins Patent Invalidation Case Against 10x Genomics in Single Cell Sequencing Dispute

The District Court for the District of Delaware granted Parse Biosciences' Motion for Summary Judgment, invalidating Scale Biosciences' (now 10x Genomics) patent 11,634,752 for lack of written description and enablement.

UCLA Launches First Large-Scale U.S. Trial Testing AI in Breast Cancer Screening

UCLA and UC Davis will co-lead the PRISM Trial, a $16 million randomized controlled study evaluating artificial intelligence support for mammogram interpretation across seven academic medical centers.

Lila Biologics Partners with Eli Lilly for AI-Driven Radioligand Therapy Development

Lila Biologics announced a global licensing and multi-target research collaboration with Eli Lilly focused on discovering and developing novel radioligand therapies for solid tumor imaging and treatment.

Novel Buprenorphine Protocol Eliminates Withdrawal Requirement for Opioid-Use Disorder Treatment

University of Washington researchers developed a new buprenorphine treatment protocol that allows patients to begin opioid-use disorder therapy without stopping fentanyl use or experiencing withdrawal symptoms.

Global Rheumatoid Arthritis Incidence Rises 13.2% Over Three Decades Despite Declining Mortality

Global rheumatoid arthritis incidence increased 13.2% from 1990 to 2021, affecting 17.9 million people worldwide by 2021, with significant regional disparities and a shift toward younger age groups.

Global Study Reveals Significant Gender Disparities in Health Outcomes

Men experience higher mortality rates from 13 of the top 20 global health conditions, with COVID-19 and heart disease showing 45% higher illness and death rates compared to women.

Stanford Researchers Develop Novel RNA Blood Test for Cancer Detection and Treatment Resistance Monitoring

Stanford Medicine researchers have developed a revolutionary blood test that analyzes cell-free RNA molecules to detect cancers at various stages, including early-stage lung cancer with 73% accuracy.

Breakthrough Diagnostic Tools for Early Fatty Liver Disease Detection: AI and Blood Tests Show Promise

New AI technology developed at University of Washington has identified hundreds of undiagnosed fatty liver disease cases by analyzing existing imaging scans, with 83% of patients with evidence of the disease lacking formal diagnosis.

Environmental Pollutants Significantly Increase Childhood Asthma Risk, New Studies Reveal

Recent research shows that ozone pollution exposure during a child's first two years increases asthma risk by 31% at ages 4-6, highlighting the need for long-term ozone regulation.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.